Actinium Pharmaceuticals Shareholders Urged to Act in Class Action Following Allegations of Misleading Information

Actinium Pharmaceuticals Shareholders' Alert

In a recent announcement from The Gross Law Firm, shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) who experienced financial losses, are being urged to take action concerning a pending class action lawsuit. This advisory targets individuals who purchased shares of ATNM during a specified timeframe and highlights crucial allegations pertaining to misleading assertions made by the company's executives.

Class Period and Allegations

The class period defined in the notice spans from October 31, 2022, to August 2, 2024. During this period, the firm claims that key representatives of Actinium Pharmaceuticals issued materially false and misleading statements regarding the status of their Phase 3 trial for Iomab-B, a targeted radiotherapy treatment.

Notably, the allegations outline several significant failures in disclosures:
1. The trial data was deemed unlikely to meet the FDA's acceptance criteria for the BLA (Biologics License Application) of Iomab-B.
2. Subsequent analyses claiming improved Overall Survival were likely insufficient to satisfy FDA expectations.
3. As a direct outcome, the FDA's review of Iomab-B was thought to be jeopardized, whether by outright refusal or lack of approval in its current format.
4. Consequently, positive statements regarding the company’s business outlook were misleading and lacked a foundation for investor trust.

Timeline for Shareholders

Potential plaintiffs are advised to act swiftly, as the deadline to apply for lead plaintiff status is approaching on May 27, 2025. Interested shareholders can register through a dedicated submission form available via grosslawfirm.com. By signing up, shareholders will join a portfolio monitoring program that offers updates on the development and status of the case, ensuring they remain informed every step of the way.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to protecting investor rights. With an established track record in class action litigations, the firm prioritizes transparency and supports investors who have suffered due to fraudulent or misleading corporate behaviors. Their goal is to restore investor confidence by holding companies accountable for corporate missteps, ensuring that responsible practices are upheld across the board.

In this rapidly evolving landscape, where investors rely heavily on accurate information for financial decisions, The Gross Law Firm stands as a beacon for those looking for justice after losses incurred due to corporate dishonesty.

For shareholders of Actinium Pharmaceuticals, the time to act is now. By exploring this opportunity, they can contribute toward a collective effort that emphasizes accountability and seeks to redress financial grievances stemming from alleged corporate misconduct.

For additional details or to initiate contact with The Gross Law Firm, reach out directly through the firm's official contact channels. Time is of the essence; ensure your voice is heard.